Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01
COPENHAGEN, Denmark, October 17, 2025 - Evaxion A/S ( NASDAQ: EVAX ) ( "Evaxion" ) , a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new two-year unprecedented clinical efficacy data of its personalized cancer vaccine EVX-01 in patients with ...
How this was made
The 30-second read
Why it matters
The trial results could accelerate EVX-01's path to market, influencing investor sentiment and biotech valuations.
Market read
High relevance for biotech investors, especially those focused on immunotherapy and personalized cancer vaccines.
What to watch
Potential safety concerns or regulatory hurdles could delay commercialization, impacting stock performance.
Background
Evaxion is developing AI-powered immunotherapies, with EVX-01 showing promising efficacy in early clinical trials.
Ticker impact
The news pertains directly to Evaxion's clinical trial results, indicating potential positive impact on its stock.
Moderate to strong upward movement in EVAX stock within the next 3-6 months, contingent on further clinical success and regulatory approval.
The reported 75% objective response rate in a phase 2 trial is a strong efficacy indicator, likely to attract investor interest and drive stock price upward, assuming no adverse safety signals.
Market effects
Potential positive impact on biotech and immunotherapy sectors, with increased investor interest in innovative cancer treatments.
Primarily affects European biotech stocks, with possible spillover to global markets due to the significance of the trial results.
Moderate; advances in personalized cancer vaccines could influence global biotech investment trends.
Counterpoint
The positive trial data may be already priced in, and subsequent results could be disappointing, leading to volatility or decline.
Key entities
- CompanyEvaxion
A clinical-stage biotech specializing in AI-immunology vaccines.


